Literature DB >> 6092098

Differentiation of two components of specific [3H]imipramine binding in rat brain.

P D Hrdina.   

Abstract

Specific binding of [3H]imipramine to membrane preparation from rat cerebral cortex can be resolved in two distinct components: the high-affinity binding with a KD in nanomolar range (6.9 +/- 0.4 nM) and a maximum number of binding sites (Bmax) 285 +/- 19 fmol/mg protein and the low-affinity component with a KD of 292 +/- 45 nM and Bmax of 2459 +/- 428 fmol/mg protein. Tricyclic antidepressants, a non-tricyclic serotonin uptake inhibitor fluoxetine and a tetracyclic antidepressant maprotiline show a markedly different pattern in displacing [3H]imipramine binding at the high- and the low-affinity site. When the high-affinity sites were protected, the differences in potency of tested drugs in displacing specific [3H]imipramine binding, and the correlation with their ability to inhibit serotonin reuptake, were not observed. The Hill coefficients of competing drugs at low-affinity sites were markedly lower (0.45-0.69) and the shape of displacement curves indicated that more than one site may be involved in low affinity binding of [3H]imipramine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6092098     DOI: 10.1016/0014-2999(84)90569-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Drug inhibition indicates a single-site model of the 5-HT uptake site/antidepressant binding site in rat and human brain.

Authors:  J O Marcusson; A Andersson; I Bäckström
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

2.  Brain 5-hydroxytryptamine uptake sites labeled with [3H]paroxetine in antidepressant drug-treated depressed suicide victims and controls.

Authors:  K M Lawrence; F De Paermentier; S Lowther; M R Crompton; C L Katona; R W Horton
Journal:  J Psychiatry Neurosci       Date:  1997-05       Impact factor: 6.186

3.  Platelet 5-HT uptake sites, labelled with [3H] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine.

Authors:  K M Lawrence; C L Katona; M T Abou-Saleh; M M Robertson; B L Nairac; D R Edwards; T Lock; R A Burns; D A Harrison; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

4.  Regional distribution of specific high affinity binding sites for 3H-imipramine and 3H-paroxetine in human brain.

Authors:  P Rosel; J M Menchon; M Oros; J Vallejo; T Cortadellas; B Arranz; P Alvarez; M A Navarro
Journal:  J Neural Transm (Vienna)       Date:  1997       Impact factor: 3.575

5.  Platelet 5-HT uptake sites in depression: three concurrent measures using [3H] imipramine and [3H] paroxetine.

Authors:  K M Lawrence; J Falkowski; R R Jacobson; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

6.  Comparative study of platelet 3H-paroxetine and 3H-imipramine binding in panic disorder patients and healthy controls.

Authors:  G Faludi; K Tekes; L Tóthfalusi
Journal:  J Psychiatry Neurosci       Date:  1994-03       Impact factor: 6.186

7.  Relationship of social support to [3H]imipramine binding during and after examination stress.

Authors:  L J Iny; B E Suranyi-Cadotte; B Bernier; L Luthe; M J Meaney
Journal:  J Psychiatry Neurosci       Date:  1993-07       Impact factor: 6.186

8.  Solubilization and characterization of [3H]imipramine and [3H]paroxetine binding sites from calf striatum.

Authors:  A Rotondo; G Giannaccini; C Quattrone; D Marazziti; C Martini; G B Cassano; A Lucacchini
Journal:  Neurochem Res       Date:  1994-10       Impact factor: 3.996

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.